Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

CVKD

Cadrenal Therapeutics Inc

Dec 13 • 04:00PM ET

11.20

Dollar change -0.40
Percentage change -3.45	%

Healthcare • Biotechnology • USA • NASD

Peers: ABBV JNJ MRK PFE LLY AMGN BMY REGN GILD VRTX

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-7.30	Insider Own	38.06%	Shs Outstand	1.23M	Perf Week	-10.76%
Market Cap	17.94M	Forward P/E	-	EPS next Y	-5.09	Insider Trans	0.00%	Shs Float	1.03M	Perf Month	-32.37%
Income	-7.61M	PEG	-	EPS next Q	-2.02	Inst Own	4.74%	Short Float	7.83%	Perf Quarter	0.67%
Sales	0.00M	P/S	-	EPS this Y	14.62%	Inst Trans	312.68%	Short Ratio	1.27	Perf Half Y	55.52%
Book/sh	2.76	P/B	4.05	EPS next Y	35.85%	ROA	-108.76%	Short Interest	0.08M	Perf Year	41.15%
Cash/sh	2.72	P/C	4.11	EPS next 5Y	-	ROE	-125.15%	52W Range	5.40 - 32.55	Perf YTD	0.91%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-222.96%	52W High	-65.59%	Beta	1.40
Dividend TTM	-	Quick Ratio	3.60	Sales past 5Y	0.00%	Gross Margin	-	52W Low	107.41%	ATR (14)	1.50
Dividend Ex-Date	-	Current Ratio	3.60	EPS Y/Y TTM	53.08%	Oper. Margin	-	RSI (14)	35.59	Volatility	12.98% 10.47%
Employees	4	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	35.67
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	-82.69%	Payout	-	Rel Volume	1.96	Prev Close	11.60
Sales Surprise	-	EPS Surprise	-13.15%	Sales Q/Q	-	Earnings	Nov 07	Avg Volume	63.73K	Price	11.20
SMA20	-18.67%	SMA50	-23.50%	SMA200	17.53%	Trades		Volume	125,025	Change	-3.45%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-18-23	Initiated	Noble Capital Markets	Outperform	$4

Nov-19-24 09:00AM	Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook (PR Newswire) -7.29%
Nov-12-24 09:00AM	CADRENAL THERAPEUTICS HIGHLIGHTS PRESENTATION AT EUROPEAN ASSOCIATION FOR CARDIO-THORACIC SURGERY (EACTS) MEDICAL CONGRESS (PR Newswire)
Nov-07-24 09:00AM	CADRENAL THERAPEUTICS PROVIDES THIRD-QUARTER CORPORATE UPDATE (PR Newswire)
Nov-01-24 08:00PM	Cadrenal Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds (PR Newswire) -18.86%
Oct-24-24 09:00AM	Cadrenal Therapeutics Raises $5.1 Million via At-The-Market Facility (PR Newswire) +17.97%
09:00AM	Loading…
Oct-23-24 09:00AM	CADRENAL THERAPEUTICS JOINS CORPORATE COUNCIL OF ANTICOAGULATION FORUM (PR Newswire)
Sep-23-24 04:15PM	Cadrenal Therapeutics to Participate in Lytham Partners Fall 2024 Investor Conference (PR Newswire) -12.17% +16.94%
Sep-11-24 01:00PM	Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing (ACCESSWIRE) +17.85%
Aug-22-24 09:00AM	Cadrenal Therapeutics Announces Upcoming Type-B FDA Meeting in September to Discuss Tecarfarin Trial in LVAD Patients (PR Newswire) -5.52%
Aug-21-24 07:00AM	Presenting on the Emerging Growth Conference 74 Day 2 on August 22 Register Now (GlobeNewswire)
Aug-20-24 09:00AM	Published Findings Highlight Tecarfarin's Potential and Reinforce Need for Better Anticoagulation Therapy in LVAD Patients (PR Newswire) +19.12%
07:00AM	Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now (GlobeNewswire)
Aug-14-24 09:00AM	Cadrenal Therapeutics to Present at Upcoming Investor Conferences (PR Newswire)
Aug-12-24 05:07PM	Cadrenal Therapeutics, Inc. (CVKD): A New Penny Stock to Buy Now (Insider Monkey) +13.67%
Aug-07-24 11:53PM	CVKD Stock Earnings: Cadrenal Therapeutics Misses EPS for Q2 2024 (InvestorPlace)
04:05PM	Loading…
04:05PM	Cadrenal Therapeutics Provides Second Quarter 2024 Corporate Update (PR Newswire)
Aug-06-24 09:00AM	Cadrenal Therapeutics and Abbott Initiate Collaborative Effort to Advance Novel Anticoagulant Tecarfarin for Patients with LVADs (PR Newswire)
Jul-17-24 09:00AM	Cadrenal Therapeutics to Present at the Emerging Growth Conference on July 18, 2024 (PR Newswire)
07:00AM	Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now (GlobeNewswire)
Jul-16-24 07:00AM	Presenting on the Emerging Growth Conference 73 Day 1 on July 17 Register Now (GlobeNewswire)
Jun-12-24 07:00AM	Presenting on the Emerging Growth Conference 72 Day 2 on June 13 Register Now (GlobeNewswire)
Jun-11-24 04:15PM	Cadrenal Therapeutics to Present at the Emerging Growth Conference on June 12, 2024 (PR Newswire) +6.34%
07:00AM	Presenting on the Emerging Growth Conference 72 Day 1 on June 12 Register Now (GlobeNewswire)
Jun-03-24 09:00AM	Cadrenal Therapeutics Highlights Presentation of New Trial Data at ISHLT Conference Demonstrating the Importance of Anticoagulation Quality in LVAD Patients (PR Newswire) +5.45%
May-23-24 09:00AM	Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024 (PR Newswire)
May-09-24 01:53PM	CVKD Stock Earnings: Cadrenal Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
09:00AM	Cadrenal Therapeutics Provides First Quarter 2024 Corporate Update (PR Newswire)
Apr-11-24 04:30PM	Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024 (PR Newswire) -5.34%
Apr-09-24 09:00AM	Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts (PR Newswire) -19.86%
Mar-11-24 09:00AM	Cadrenal Therapeutics Provides Fourth Quarter 2023 Corporate Update (PR Newswire)
09:00AM	Loading…
Feb-26-24 09:00AM	Cadrenal Therapeutics to Participate at Technology and Heart Failure Therapeutics (THT) Conference (PR Newswire)
Feb-08-24 09:00AM	Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal Trial (PR Newswire) -19.47%
Jan-31-24 09:00AM	Cadrenal Therapeutics Highlights Publication of Peer-Reviewed Article Supporting Need for New Anticoagulation Therapy for Patients with Certain Medical Conditions (PR Newswire) +8.33%
Jan-24-24 09:00AM	Cadrenal Therapeutics to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024 (PR Newswire) +19.25%
Jan-04-24 09:00AM	Cadrenal Therapeutics to Present at the Biotech Showcase on January 8, 2024 Alongside the J.P. Morgan Annual Healthcare Conference (PR Newswire)
Dec-19-23 09:00AM	Noble Capital Markets Initiates Coverage on Cadrenal Therapeutics with Outperform Rating and US$4.00 Price Target (PR Newswire) +6.94%
Dec-12-23 09:00AM	Cadrenal Therapeutics Engages The Sage Group to Advance Tecarfarin's Late-Stage Development and Commercialization (PR Newswire)
Nov-30-23 04:15PM	Cadrenal Therapeutics to Present at the NobleCon 19 Conference on December 4, 2023 (PR Newswire) +8.70%
Nov-09-23 09:00AM	Cadrenal Therapeutics Provides Third Quarter 2023 Corporate Update (PR Newswire) -5.38%
Oct-16-23 08:38AM	Innovation Takes Center Stage: Florida's Life Sciences Leaders Shine at BioFlorida Conference (PR Newswire)
Oct-09-23 04:15PM	Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2023 Investor Conference (PR Newswire)
Sep-05-23 08:00AM	Cadrenal Therapeutics Highlights Additional Need for a New Vitamin K Antagonist (Tecarfarin) Following Updates from the Recent European Society of Cardiology Congress (PR Newswire)
Aug-30-23 08:00AM	Cadrenal Therapeutics Expands Evaluation of Tecarfarin for Patients with Antiphospholipid Syndrome (APS) (PR Newswire)
Aug-28-23 04:15PM	Cadrenal Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference (PR Newswire)
Aug-10-23 09:00AM	Cadrenal Therapeutics Provides Second Quarter 2023 Corporate Update (PR Newswire)
Aug-01-23 09:00AM	Cadrenal Therapeutics Expands Focus for Tecarfarin to Patients with Implanted Medical Devices for Heart Diseases (PR Newswire)
Jul-24-23 09:00AM	Cadrenal Therapeutics Announces Appointment of Robert Lisicki to Board of Directors (PR Newswire) -11.65%
Jul-14-23 03:02PM	Cadrenal Therapeutics Announces Closing of $7.5 Million Private Placement Priced At-the-Market under Nasdaq Rules (PR Newswire) -18.37%
Jul-12-23 03:17PM	Cadrenal Therapeutics Announces $7.5 Million Private Placement Priced At-the-Market under Nasdaq Rules (PR Newswire) +29.31%
Jun-28-23 06:23AM	The 3 Hottest IPOs to Buy Before They Soar (InvestorPlace)
Jun-01-23 09:00AM	Cadrenal Therapeutics to Participate in the 2023 BIO International Convention in Boston (PR Newswire)
May-10-23 09:00AM	Cadrenal Therapeutics Provides First Quarter 2023 Corporate Update (PR Newswire)
May-09-23 04:30PM	Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2023 Investor Conference (PR Newswire)
Mar-30-23 09:00AM	Cadrenal Therapeutics Provides Fiscal Year 2022 Corporate Update (PR Newswire) +8.53%
Mar-09-23 09:00AM	Cadrenal Therapeutics Recognizes National Kidney Month with Goal to Advance Tecarfarin for Severely Underserved Patient Population (PR Newswire) -7.69%
Feb-08-23 09:00AM	Cadrenal Therapeutics to Ring the NASDAQ Stock Market Closing Bell on February 8, 2023 (PR Newswire) -9.26%
Feb-06-23 09:00AM	Cadrenal Therapeutics to Participate in the 2023 BIO CEO & Investor Conference (PR Newswire) -6.25%
Feb-01-23 09:00AM	Cadrenal Therapeutics Announces Formation of Scientific Advisory Board (PR Newswire)
Jan-24-23 02:11PM	Cadrenal Therapeutics (Nasdaq: CVKD) Announces Closing of Initial Public Offering (PR Newswire) -18.37%
Jan-23-23 11:39AM	What's Going On With Cadrenal Therapeutics Stock Today (Benzinga)
08:30AM	Cadrenal Therapeutics (Nasdaq: CVKD) Granted FDA Fast Track Designation for Tecarfarin for Prevention of Systemic Thromboembolism of Cardiac Origin in Patients with End-Stage Renal Disease and Atrial Fibrillation (PR Newswire)
Jan-20-23 09:31AM	Cadrenal Therapeutics Announces Pricing of Initial Public Offering (IPO) (PR Newswire)

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focused on developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang Pham and Matthew Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CVKD

Cadrenal Therapeutics Inc

Upgrade your FINVIZ experience